ENG
Liver Cancer Diagnostics Market: Global Industry Analysis and Forecast (2024-2030) by Test Type, End-use, and, Region.
Liver Cancer Diagnostics Market size was valued at US$ 12.04 Billion in 2023 and the Liver Cancer Diagnostics revenue is expected to grow at 7.5% through 2024 to 2030, reaching nearly US$ 19.97 Billion.
Format : PDF | Report ID : SMR_268
Liver Cancer Diagnostics Market Definition & Overview:
Liver cancer is one of the top causes of cancer mortality worldwide. According to the American Cancer Society, the incidence of liver cancer has more than quadrupled in the last few decades, and the fatality rate has more than doubled. According to the same source, about 42,230 new cases of liver cancer detected in the United States in 2021, resulting in approximately 30,230 fatalities. Chronic viral hepatitis, Cirrhosis, high alcohol intake, cigarette use, and obesity are all key risk factors for this condition. Early detection and identification of liver cancer are critical for reducing mortality, creating a strong need for novel diagnostic tools. Liver Cancer Diagnostics Market's segment analysis is studied on the basis of test type, end use and region.
To get more Insights: Request Free Sample Report
Liver Cancer Diagnostics Market Dynamics:
According to Globocan statistics, liver cancer was the 6th most frequent kind of cancer in 2020, with around 905,677 new instances of this life-threatening disease being identified globally, resulting in approximately 830,180 fatalities. Chronic (long-term) infection with Hepatitis C Virus (HCV) or Hepatitis B Virus is the most prevalent cause of liver cancer (HBV). According to WHO estimates, 71.0 million persons worldwide have chronic HCV infection. According to the same source, over 399,000 persons died in 2016 as a result of cirrhosis and primary liver cancer caused by HCV infection. Because of the disease's high incidence and death rate, the need for novel diagnostic methods for prompt diagnosis has increased dramatically, driving the liver cancer diagnostics market growth.
Additionally, an increase in the number of initiatives aimed at raising awareness about early detection of liver cancer is likely to be a major driver driving up demand for its diagnostic tools globally. The National Cancer Institute (NCI) supported a research study at Michigan Medicine in 2018 to improve liver cancer monitoring and early diagnosis in the United States. Collaborations and partnerships between the National Cervical Cancer Coalition, the World Health Organization, the Centers for Disease Control and Prevention, the United States Preventive Services Task Force, and others to increase liver cancer screening are also expected to boost liver cancer diagnostics market growth during the forecast period.
Liver Cancer Diagnostics Market Segment Analysis:
The laboratory tests segment dominated the liver cancer diagnostics market in 2023, accounting for 39.5 percent of total revenue. During the forecast period, the segment is expected to increase at the quickest rate. The strong preference for laboratory tests owing to their correctness and cost-efficiency can be linked to their big market and growth. Laboratory tests are also used to assess high-risk individuals, determine therapy options, determine disease stages, and determine how well the illness is responding to treatment.
Over the forecast period, hospital-affiliated laboratories are estimated to account for the vast majority of revenue in the worldwide liver cancer diagnostics business. Increasing emphasis on operations that need a medical setting and tests that require hospitalization, as well as increased demand for biopsy for liver cancer diagnostics, are some of the primary reasons driving liver cancer diagnostics market expansion for hospital-associated labs.
Liver Cancer Diagnostics Market Regional Insights:
North America dominated the liver cancer diagnostics market in 2023, accounting for 40.1 percent of total revenue, and is expected to continue to do so throughout the forecast period. This region's dominance is due to its well-established healthcare infrastructure, effective health-insurance policies, and widespread use of modern diagnostic technologies. Because of the greater frequency of hepatocellular carcinoma and strong knowledge about early diagnosis, the United States controls the market share in North America. In the United States, Market size was valued at US$ 8.2 billion in 2020.
The liver cancer diagnostics market in the Asia Pacific is expected to grow at the fastest rate throughout the research period. The high frequency of hepatitis in developing countries such as India and China is responsible for this rapid development. Increased government attempts to raise awareness about early identification of liver cancer, as well as increased alcohol and cigarette usage in the region, are further factors impacting the market growth.
China, the world's second-biggest economy, is expected to reach a market size of US$9.1 million by 2030, with an annual growth rate of 8.3% from 2020 to 2027. Japan and Canada are two more important geographic markets, with forecasted growth rates of 2.9 percent and 4.8 percent, respectively, from 2020 to 2027. Germany is expected to expand at a CAGR of around 3.3 percent in Europe.
The objective of the report is to present a comprehensive analysis of the Liver Cancer Diagnostics Market to the stakeholders in the industry. The report provides trends that are most dominant in the Liver Cancer Diagnostics Market and how these trends will influence new business investments and market development throughout the forecast period. The report also aids in the comprehension of the global market dynamics and competitive structure of the market by analyzing market leaders, market followers, and regional players.
The qualitative and quantitative data provided in the Liver Cancer Diagnostics Market report is to help understand which market segments, regions are expected to grow at higher rates, factors affecting the market, and key opportunity areas, which will drive the industry and market growth through the forecast period. The report also includes the competitive landscape of key players in the industry along with their recent developments in the Liver Cancer Diagnostics Market. The report studies factors such as company size, market share, market growth, revenue, production volume, and profits of the key players in the global market.
The report provides Porter's Five Force Model, which helps in designing the business strategies in the market. The report helps in identifying how many rivals are existing, who they are, and how their product quality is in the Market. The report also analyses if the Liver Cancer Diagnostics Market is easy for a new player to gain a foothold in the market, do they enter or exit the market regularly if the market is dominated by a few players, etc.
Liver Cancer Diagnostics Market Scope:
|
Liver Cancer Diagnostics Market |
|
|
Market Size in 2023 |
USD 12.04 Bn. |
|
Market Size in 2030 |
USD 19.97 Bn. |
|
CAGR (2024-2030) |
7.5% |
|
Historic Data |
2018-2022 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2030 |
|
Segment Scope |
by Test Type
|
|
By End-use
|
|
|
Regional Scope |
North America- United States, Canada, and Mexico Europe – UK, France, Germany, Italy, Spain, Sweden, Austria, and Rest of Europe Asia Pacific – China, India, Japan, South Korea, Australia, ASEAN, Rest of APAC Middle East and Africa - South Africa, GCC, Egypt, Nigeria, Rest of the Middle East and Africa South America – Brazil, Argentina, Rest of South America |
Liver Cancer Diagnostics Market Players:
- Abbott Laboratories (United States)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Qiagen N.V. (Germany)
- Thermo Fisher Scientific, Inc. (United States)
- Siemens Healthineers (Germany)
- Becton Dickinson & Company (United States)
- Illumina, Inc. (United States)
- Koninklijke Philips N.V. (Netherlands)
- Epigenomics AG (Germany)
- Fujifilm Medical Systems U.S.A., Inc. (United States)
- Hologic, Inc. (United States)
- Thermo Fisher Scientific, Inc. (United States)
- Biocept, Inc. (United States)
- Danaher (United States)
- Foundation Medicine, Inc., (United States)
Frequently Asked Questions
disease's high incidence and death rate, the need for novel diagnostic methods for prompt diagnosis has increased dramatically, driving the market growth.
North America dominated the liver cancer diagnostics market in 2020, accounting for 40.1 percent of total revenue, and is expected to continue to do so throughout the forecast period.
The high frequency of hepatitis in developing countries such as India and China is responsible for this rapid development.
Abbott Laboratories, F. Hoffmann-La Roche Ltd., Qiagen N.V., Thermo Fisher Scientific, Inc., Siemens Healthineers, and Becton Dickinson & Company.
Chapter 1 Scope of the Report
Chapter 2 Research Methodology
2.1.Research Process
2.2.Global Liver Cancer Diagnostics Market: Target Audience
2.3.Global Liver Cancer Diagnostics Market: Primary Research (As per Client Requirement)
2.4.Global Liver Cancer Diagnostics Market: Secondary Research
Chapter 3 Executive Summary
Chapter 4 Competitive Landscape
4.1.Market Share Analysis, By Value, 2023-2030
4.1.1.Market Share Analysis, By Region, By Value, 2023-2030 (In %)
4.1.1.1.North America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.2.Europe Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.3.Asia Pacific Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.4.South America Market Share Analysis, By Value, 2023-2030 (In %)
4.1.1.5.The Middle East and Africa Market Share Analysis, By Value, 2023-2030 (In %)
4.1.2.Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.1.North America Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.1.1.USA Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.1.2.Canada Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.1.3.Mexico Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.Europe Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.1.UK Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.2.France Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.3.Germany Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.4.Italy Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.5.Spain Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.6.Sweden Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.7.Austria Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.2.8.Rest of Europe Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3. Asia Pacific Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.1.China Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.2.India Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.3.Japan Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.4.South Korea Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.5.Australia Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.6.ASEAN Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.3.7.Rest of APAC Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.4. South America Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.4.1.Brazil Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.4.2.Argentina Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.4.3.Rest of South America Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.5. Middle East and Africa Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.5.1.South Africa Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.5.2.GCC Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.5.3.Egypt Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.5.4.Nigeria Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.2.5.5.Rest of Middle East and Africa Market Share Analysis, By Test Type, By Value, 2023-2030 (In %)
4.1.3.Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.North America Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.1.1.USA Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.1.2.Canada Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.1.3.Mexico Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2. Europe Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.1.UK Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.2.France Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.3.Germany Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.4.Italy Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.5.Spain Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.6.Sweden Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.7.Austria Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.2.8.Rest of Europe Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3. Asia Pacific Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.1.China Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.2.India Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.3.Japan Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.4.South Korea Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.5.Australia Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.6.ASEAN Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.3.7.Rest of APAC Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.4.South America Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.4.1.Brazil Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.4.2.Argentina Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.4.3.Rest of South America Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.5.Middle East and Africa Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.5.1.South Africa Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.5.2.GCC Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.5.3.Egypt Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.5.4.Nigeria Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.1.4.5.5.Rest of Middle East and Africa Market Share Analysis, By End-use, By Value, 2023-2030 (In %)
4.2.Stellar Competition matrix
4.2.1.Global Stellar Competition Matrix
4.2.2.North America Stellar Competition Matrix
4.2.3.Europe Stellar Competition Matrix
4.2.4.Asia Pacific Stellar Competition Matrix
4.2.5.South America Stellar Competition Matrix
4.2.6.Middle East and Africa Stellar Competition Matrix
4.3. Key Players Benchmarking
4.3.1.Key Players Benchmarking By Test Type, Pricing, Market Share, Investments, Expansion Plans, Physical Presence and Presence in the Market.
4.4. Mergers and Acquisitions in Industry
4.4.1.M&A by Region, Value and Strategic Intent
4.5.Market Dynamics
4.5.1.Market Drivers
4.5.2.Market Restraints
4.5.3.Market Opportunities
4.5.4.Market Challenges
4.5.5.PESTLE Analysis
4.5.6.PORTERS Five Force Analysis
4.5.7.Value Chain Analysis
Chapter 5 Global Liver Cancer Diagnostics Market Segmentation: By Test Type
5.1.Global Liver Cancer Diagnostics Market, By Test Type, Overview/Analysis, 2023-2030
5.2.Global Liver Cancer Diagnostics Market, By Test Type, By Value, Market Share (%), 2023-2030 (USD Million)
5.3.Global Liver Cancer Diagnostics Market, By Test Type, By Value, -
5.3.1.Product Segment 1
5.3.2.Product Segment 2
Chapter 6 Global Liver Cancer Diagnostics Market Segmentation: By End-use
6.1.Global Liver Cancer Diagnostics Market, By End-use,Overview/Analysis, 2023-2030
6.2.Global Liver Cancer Diagnostics Market Size, By End-use, By Value, Market Share (%), 2023-2030 (USD Million)
6.3.Global Liver Cancer Diagnostics Market, By End-use, By Value, -
6.3.1.End User Application Segment 1
6.3.2.End User Application Segment 2
Chapter 7 Global Liver Cancer Diagnostics Market Segmentation: By Region
7.1.Global Liver Cancer Diagnostics Market, By Region – North America
7.1.1.North America Liver Cancer Diagnostics Market Size, By Test Type, By Value, 2023-2030 (USD Million)
7.1.2.North America Liver Cancer Diagnostics Market Size, By End-use, By Value, 2023-2030 (USD Million)
7.1.3.By Country – U.S.
7.1.3.1.U.S. Liver Cancer Diagnostics Market Size, By Test Type, By Value, 2023-2030 (USD Million)
7.1.3.2.U.S. Liver Cancer Diagnostics Market Size, By End-use, By Value, 2023-2030 (USD Million)
7.1.3.3.Canada Liver Cancer Diagnostics Market Size, By Value, 2023-2030 (USD Million)
7.1.3.4.Mexico Liver Cancer Diagnostics Market Size, By Value, 2023-2030 (USD Million)
7.2. Europe Liver Cancer Diagnostics Market Size, By Value, 2023-2030 (USD Million)
7.2.1.UK
7.2.2.France
7.2.3.Germany
7.2.4.Italy
7.2.5.Spain
7.2.6.Sweden
7.2.7.Austria
7.2.8.Rest of Europe
7.3. Asia Pacific Liver Cancer Diagnostics Market Size, By Value, 2023-2030 (USD Million)
7.3.1.China
7.3.2.India
7.3.3.Japan
7.3.4.South Korea
7.3.5.Australia
7.3.6.ASEAN
7.3.7.Rest of APAC
7.4. Middle East and Africa Liver Cancer Diagnostics Market Size, By Value, 2023-2030 (USD Million)
7.4.1.South Africa
7.4.2.GCC
7.4.3.Egypt
7.4.4.Nigeria
7.4.5.Rest of Middle East and Africa
7.5. South America Liver Cancer Diagnostics Market Size, By Value, 2023-2030 (USD Million)
7.5.1.Brazil
7.5.2.Argentina
7.5.3.Rest of South America
Chapter 8 Company Profiles
8.1. Key Players
8.1.1.Abbott Laboratories
8.1.1.1.Company Overview
8.1.1.2.Product Portfolio
8.1.1.3.Financial Overview
8.1.1.4.Business Strategy
8.1.1.5.Key Developments
8.1.2.Abbott Laboratories
8.1.3.Qiagen N.V.
8.1.4.F. Hoffmann-La Roche Ltd.
8.1.5.Thermo Fisher Scientific, Inc.
8.1.6.Siemens Healthineers
8.1.7.Becton Dickinson & Company
8.1.8.Illumina, Inc.
8.1.9.Koninklijke Philips N.V.
8.1.10.Epigenomics AG
8.1.11.Fujifilm Medical Systems U.S.A., Inc.
8.1.12.Hologic, Inc.
8.1.13.Thermo Fisher Scientific, Inc.
8.1.14.Biocept, Inc.
8.1.15.Danaher
8.1.16.Foundation Medicine, Inc.,
8.2. Key Findings
8.3. Recommendations
